What is the price of CRISPR Therapeutics (CRSP) today?

The current price of CRISPR Therapeutics (CRSP) is $ 50.36, representing a 36.63% gain over the past year. The stock began the year trading around $ 52.44 and is currently priced at $ 50.36. You can follow the real-time price chart, review historical performance, and track broader market trends directly on the platform.

When does CRISPR Therapeutics (CRSP) pay dividends?

CRISPR Therapeutics (CRSP) did not pay dividends over the past year.

Is CRISPR Therapeutics (CRSP) a good investment?

CRISPR Therapeutics (CRSP) is currently trading at $ 50.36 with a P/E ratio of -8.50. This represents a -1,273% premium compared to its historical average P/E. Over the past year, the stock has gained 36.63 and paid $ 0.00 in dividends, resulting in a dividend yield of 0.00%. The total shareholder return over the same period was 36.63%.Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy CRISPR Therapeutics (CRSP) stock?

You can buy CRISPR Therapeutics (CRSP) shares through any brokerage account that provides access to U.S. stock exchanges. After opening and funding your account, simply search for the ticker symbol CRSP and place a buy order. Before investing, consider factors such as your financial goals, risk tolerance, and overall portfolio allocation.

How much would 100 shares of CRISPR Therapeutics (CRSP) yield today?

Over the past month, CRISPR Therapeutics (CRSP) has returned -8.74% — 36.63% over the past year, and -56.70% over the past five years, including price appreciation and dividends.In the last 12 months, the company paid a total of 0.00 per share in dividends, resulting in a dividend yield of 0.00%.If you were to purchase 100 shares of CRISPR Therapeutics (CRSP) today at the current price of $ 50.36 your total investment would be $ 5,036.00.Based on historical performance, the investment would have grown to approximately:$ 6,880.69 after 1 year$ 2,180.59 after 5 years$ 5,036.00 after 10 yearsPast performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

CRISPR Therapeutics (CRSP): Stock Price, Earnings & Key Metrics

	p/e	p/bv	ROE	dy	market cap	net margin
JNJ	26.67	6.91	25.92%	2.23%	$ 561.22 B	21.83%
PFE	19.36	1.60	8.29%	6.75%	$ 145.01 B	11.83%
ABBV	105.03	-57.74	-54.98%	3.12%	$ 381.79 B	5.79%
NVO	10.53	6.36	60.40%	4.15%	$ 199.76 B	37.15%
MRK	33.87	6.59	19.45%	2.71%	$ 302.60 B	13.59%
AZN	27.89	6.11	21.93%	1.71%	$ 289.71 B	17.19%
GILD	18.11	7.12	39.33%	2.37%	$ 166.88 B	30.99%
BMY	16.66	6.03	36.19%	4.20%	$ 121.18 B	15.01%
ZTS	12.98	10.61	81.75%	2.50%	$ 34.32 B	27.79%
REGN	15.02	2.11	14.08%	0.56%	$ 66.44 B	29.65%
HALO	23.11	36.70	158.82%	0.00%	$ 8.06 B	23.13%
AMGN	23.49	19.94	84.87%	2.85%	$ 183.22 B	20.96%
MCK	19.63	-112.06	-570.98%	0.41%	$ 93.46 B	1.18%
HRMY	12.01	1.92	16.00%	0.00%	$ 1.75 B	16.20%
VRTX	25.44	5.70	22.41%	0.00%	$ 110.37 B	35.51%
CAH	30.33	-17.65	-58.20%	1.02%	$ 47.16 B	0.62%
ADMA	11.76	4.98	42.37%	0.00%	$ 1.94 B	32.43%
BIIB	20.76	1.53	7.36%	0.00%	$ 28.48 B	13.81%

CRISPR Therapeutics AG operates in the healthcare sector, within the biotechnology industry focused on gene-editing and genome-based therapies. The company develops treatments based on CRISPR-Cas9 technology, aimed at modifying DNA to address complex diseases.

Its main areas of activity include:

• Development of gene therapies using CRISPR-Cas9 technology.
• Clinical programs targeting blood disorders and rare diseases.
• Research in oncology, immunotherapy and metabolic conditions.
• Biotechnology platforms for genome-editing innovation.

The company’s portfolio consists of therapies in clinical development, using both ex vivo and in vivo gene-editing approaches to treat conditions such as sickle cell disease and other genetic disorders.

CRISPR Therapeutics operates internationally, with a primary presence in the United States and Europe. Its structure includes research centers, clinical-development teams, regulatory units and partnerships with pharmaceutical companies and academic institutions.

Industry dynamics affecting the company include regulatory frameworks for advanced therapies, competition within the biotechnology sector, high R&D costs, clinical trial outcomes and the growing demand for precision medicine.

Shares of CRISPR Therapeutics AG trade on the Nasdaq under the ticker CRSP.

History and Development

CRISPR Therapeutics was founded in 2013 in Switzerland with the objective of translating CRISPR-Cas9 gene-editing technology into therapeutic applications.

In its early years, the company focused on validating its scientific platform, building intellectual property and establishing a pipeline of potential treatments. Initial progress included preclinical research and the development of early-stage therapeutic programs targeting genetic diseases.

As the company evolved, it expanded its clinical pipeline and formed strategic partnerships with global pharmaceutical companies to support development and commercialization efforts. In 2016, CRISPR Therapeutics completed its initial public offering (IPO) on the Nasdaq, securing funding to advance its clinical programs and expand research capabilities.

In recent years, the company has advanced multiple therapies into clinical trials, particularly in hematology and oncology, while refining its gene-editing technologies.

CRSP

CRISPR Therapeutics AG

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment CRSP

review the fundamentals of CRISPR Therapeutics shares

P/E

P/S (PSR)

P/BV

DIVIDEND YIELD (DY)

ROA

ROE

ROIC

NET MARGIN

GROSS MARGIN

OPERATING MARGIN

EV/EBITDA

EV/EBIT

PRICE-TO-ASSETS

BVPS

EPS

EQUITY-TO-ASSETS RATIO

LIABILITIES / ASSETS

CAGR REVENUE 5 YEARS

CAGR PROFIT 5 YEARS

current DY: 0.00%

5-year average DY: 0.00%

ABOUT CRISPR Therapeutics

CRISPR Therapeutics AG

United States

13 years

2016

93

History and Development

Additional Information

PROFIT X PRICE CRSP

Financial Results CRSP

CRSP cash flow

Asset, Revenue and Profit Growth - CRSP

CRSP balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

MRK - Merck & Co.

AZN - AstraZeneca

ABBV - AbbVie

NVO - Novo Nordisk